Canadian sculptors create tariff carve-out
SIOUX FALLS, SD (KELO) — Crews have begun installing some of the new sculptures that will be featured in this year's SculptureWalk display in downtown Sioux Falls.
This year's exhibit features 80 sculptures including a piece by an artist from Canada, who says sheer luck prevented him from having to pay a tariff on his work.
Falls Park Farmer's Market returns with winter plans
'Darn windy here, aye?'
Artists like Peter Vogelaar of British Columbia face a whirlwind of paperwork in bringing their sculptures into the United States.
'It's actually more complicated than you believe. I have to deal with normally a broker in Canada to handle the border crossing,' Vogelaar said.
Vogelaar says the process has been further complicated by tariffs imposed on Canadian products coming into the United States, including his artwork.
'This year, if I brought my piece directly from Canada, I would have had to pay a duty of 25-percent. Luckily, the piece I got accepted this year is already in the U.S., so I'm just going to move it around,' Vogelaar said.
Vogelaar's piece for this year's SculptureWalk is currently in Mankato, Minnesota. He'll deliver it to Sioux Falls on Saturday.
SculptureWalk organizers say they doubt that tariffs will have a chilling effect on artists who want to bring their work here to be displayed.
'I know one of the other artists from Canada shipped a piece up here from Texas. It was on display in Texas, so it came up here so they avoid the tariffs and all of those kind of things. But, the artists are resilient and SculptureWalk is resilient, so we're just finding ways around some of these issues as they pop up,' SculptureWalk board member Jim Mathis said.
Vogelaar says he might not have brought his work to Sioux Falls if he had to pay a tariff. He says SculptureWalk is a valuable point of entry for international artists in getting their works exposed to art lovers everywhere.
Even though the SculptureWalk pieces are here for show, Vogelaar says they can be subject to tariffs because of the potential of them being sold in the United States.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
27 minutes ago
- Associated Press
Theralase Completes Annual General and Special Meeting
Toronto, Ontario--(Newsfile Corp. - June 12, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ('Theralase®" or the 'Company'), a clinical stage pharmaceutical company pioneering light, radiation, sound and drug-activated therapeutics for the treatment of cancer, bacteria and viruses, is pleased to announce the successful completion of its Annual General and Special Meeting ('AGSM'), which was held on Wednesday, June 11 th, 2025, at the Company's head office in Toronto, Ontario, Canada. Following shareholder approval on various resolutions and formal conclusion of the AGSM meeting, Theralase® hosted a virtual corporate presentation via Zoom to provide shareholders with an in-depth overview of the Company's strategic objectives and upcoming milestones for 2025 and 2026. The presentation highlighted current and planned clinical development programs focused on accelerating the commercialization of Theralase®'s innovative therapeutic technologies. For those unable to attend the live virtual session, an archived recording of the presentation can be accessed via the following link: Watch the AGSM Virtual Presentation here: AGSM Virtual Presentation Recording - Presented June 11th, 2025 Theralase® wishes to thank its shareholders and stakeholders for their ongoing support as the Company advances on its mission to commercialize safe and effective therapeutics to destroy various cancers, bacteria and viruses, with minimal impact on healthy tissue. About Theralase® Technologies Inc.: Theralase® is a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and drug-activated small molecule compounds and their associated formulations, with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses, with minimal impact on surrounding healthy tissue. Additional information is available at and Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Forward Looking Statements This news release contains Forward-Looking Statements ('FLS') within the meaning of applicable Canadian securities laws. Such statements include; but, are not limited to statements regarding the Company's proposed development plans with respect to small molecules and their drug formulations. FLS may be identified by the use of the words 'may, 'should', 'will', 'anticipates', 'believes', 'plans', 'expects', 'estimate', 'potential for' and similar expressions; including, statements related to the current expectations of the Company's management regarding future research, development and commercialization of the Company's small molecules; their drug formulations; preclinical research; clinical studies and regulatory approvals. These statements involve significant risks, uncertainties and assumptions; including, the ability of the Company to fund and secure the regulatory approvals to successfully complete various clinical studies in a timely fashion and implement its development plans. Other risks include: the ability of the Company to successfully commercialize its small molecule and drug formulations; the risk that access to sufficient capital to fund the Company's operations may not be available on terms that are commercially favorable to the Company or at all; the risk that the Company's small molecule and formulations may not be effective against the diseases tested in its clinical studies; the risk that the Company fails to comply with the terms of license agreements with third parties and as a result loses the right to use key intellectual property in its business; the Company's ability to protect its intellectual property; the timing and success of submission, acceptance and approval of regulatory filings. Many of these factors that will determine actual results are beyond the Company's ability to control or predict. Readers should not unduly rely on these FLS, which are not a guarantee of future performance. There can be no assurance that FLS will prove to be accurate as such FLS involve known and unknown risks, uncertainties and other factors which may cause actual results or future events to differ materially from the FLS. Although the FLS contained in the press release are based upon what management currently believes to be reasonable assumptions, the Company cannot assure prospective investors that actual results, performance or achievements will be consistent with these FLS. All FLS are made as of the date hereof and are subject to change. Except as required by law, the Company assumes no obligation to update such FLS. For investor information on the Company, please feel to reach out Investor Inquiries - Theralase Technologies. For More Information: (843-5273) (5273) Kristina Hachey, CPA Chief Financial Officer X 224 [email protected] To view the source version of this press release, please visit
Business Wire
35 minutes ago
- Business Wire
FDA Grants Priority Review for Zoliflodacin New Drug Application for the Treatment of Uncomplicated Gonorrhea and Assigns Target PDUFA Date of December 15, 2025
WALTHAM, Mass. & GENEVA--(BUSINESS WIRE)--Innoviva Specialty Therapeutics, Inc., a subsidiary of Innoviva, Inc. (NASDAQ: INVA), in collaboration with the Global Antibiotic Research & Development Partnership (GARDP), today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review for the New Drug Application (NDA) for zoliflodacin, an investigational first-in-class, single dose, spiropyrimidinetrione oral antibiotic for the treatment of uncomplicated gonorrhea in adults and pediatric patients 12 years and older. The FDA assigned a target action date of December 15, 2025 under the Prescription Drug User-Fee Act (PDUFA). It is expected the FDA will notify Innoviva Specialty Therapeutics regarding the FDA's decision to conduct an Advisory Committee Meeting in the Day 74 letter. If approved, zoliflodacin would be the first new antibiotic for treating gonorrhea in decades. The U.S. FDA has granted zoliflodacin a Qualified Infectious Disease Product (QIDP) designation. This designation allows it to benefit from FDA Priority Review, and Extended Market Exclusivity. Entasis Therapeutics, Inc., the legal NDA holder and affiliate of Innoviva Specialty Therapeutics, Inc., retains the commercial rights for zoliflodacin in the major markets in North America, Europe, and Asia-Pacific. GARDP retains the right to register and commercialize the product in more than three-quarters of the world's countries, including all low-income countries, most middle-income countries, and several high-income countries. GARDP is committed to working with its partners and local health authorities in markets where zoliflodacin receives regulatory approval to help remove access barriers to ensure treatment is available to address unmet medical needs while ensuring appropriate and sustainable use. About Uncomplicated Gonorrhea With more than 82 million new gonorrhea infections occurring globally each year, gonorrhea is the second most common bacterial sexually transmitted infection (STI), affecting both men and women, which, if left untreated, can result in serious and permanent health consequences. With the rise and spread of drug-resistant infections, the World Health Organization (WHO) has identified antimicrobial resistance (AMR) as one of the ten most critical global threats to public health. The bacterium Neisseria gonorrhoeae, which causes gonorrhea, has progressively developed resistance to most classes of antibiotics used to treat these infections, including ceftriaxone, a widely used intramuscular injection that was first made available in 1984. About Zoliflodacin Zoliflodacin is an investigational first-in-class antibacterial that is administered in a single oral dose for the treatment of uncomplicated gonorrhea. The oral route of administration simplifies treatment by providing a convenient option for patients unable to receive an intramuscular injection. Zoliflodacin has a unique mechanism of action, inhibiting a crucial bacterial enzyme called type II topoisomerase, which is essential for bacterial function and reproduction. In in vitro studies, zoliflodacin demonstrated activity against multidrug-resistant strains of Neisseria gonorrhoeae, including those resistant to ceftriaxone and azithromycin, with no cross-resistance to other antibiotics. In a pivotal Phase 3 clinical trial, zoliflodacin demonstrated non-inferiority in achieving microbiological cure at the urogenital site of infection with a single oral dose of zoliflodacin compared to a treatment regimen of a single intramuscular injection of 500mg ceftriaxone followed by 1g of oral azithromycin. The Phase 3 study found that zoliflodacin was generally well-tolerated, with no serious adverse events or deaths reported during the trial. About GARDP The Global Antibiotic Research & Development Partnership (GARDP) is a not-for-profit global health organization driven to protect people from the rise and spread of drug-resistant infections, one of the biggest threats to us all. By forging the public and private partnerships that matter, we develop and make accessible antibiotic treatments for people who need them. Vital support for our work comes from the governments of Canada, Germany, Japan, Monaco, the Netherlands, Switzerland, the United Kingdom, the Canton of Geneva, the European Union, as well as the Gates Foundation, Global Health EDCTP3, GSK, the RIGHT Foundation, the South African Medical Research Council (SAMRC) and Wellcome. About Innoviva Innoviva is a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ('IST'), and a portfolio of strategic investments in healthcare assets. Innoviva's royalty portfolio includes respiratory assets partnered with Glaxo Group Limited ('GSK'). Innoviva is entitled to receive royalties from GSK on sales of RELVAR ® /BREO ® ELLIPTA ® and ANORO ® ELLIPTA ®. Innoviva's other innovative healthcare assets include infectious disease and critical care assets stemming from acquisitions of Entasis Therapeutics, including XACDURO ® (sulbactam for injection; durlobactam for injection), co-packaged for intravenous use approved for the treatment of adults with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible strains of Acinetobacter baumannii-calcoaceticus complex and the investigational zoliflodacin currently being developed for the treatment of uncomplicated gonorrhea, and La Jolla Pharmaceutical Company, including GIAPREZA ® (angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock and XERAVA ® (eravacycline) for the treatment of complicated intra-abdominal infections in adults. Innoviva also markets ZEVTERA® (ceftobiprole), an advanced-generation cephalosporin antibiotic, in the U.S. through an exclusive license from Basilea Pharmaceutica International Ltd, Allschwil. For more information about Innoviva, go to For information about Innoviva Specialty Therapeutics, go to ANORO ®, RELVAR ® and BREO ® are trademarks of the GSK group of companies. ZEVTERA ® is a trademark of Basilea Pharmaceutica Ltd, Allschwil.
Business Wire
35 minutes ago
- Business Wire
DATA Communications Management Corp. and Atlantic Packaging Products Highlight Reforestation Efforts
BRAMPTON, Ontario--(BUSINESS WIRE)--DATA Communications Management Corp. (TSX: DCM; OTCQX: DCMDF) ('DCM' or the "Company"), a leading Canadian provider of print and digital solutions that help simplify complex marketing communications and workflow, is excited to announce that its client, Atlantic Packaging Products Ltd. ('Atlantic Packaging'), has hit a significant milestone through its participation in the PrintReleaf program: over 50,000 trees planted at reforestation projects around the world. The PrintReleaf initiative is a crucial pillar of DCM's sustainability strategy aimed at mitigating its environmental impact. PrintReleaf offers a software platform that measures paper consumption, calculates how many trees were harvested to produce that paper and replants the exact number of trees at global reforestation projects. Since Atlantic Packaging Products joined the program in March 2022, DCM has planted 55,936 trees 1 on their behalf at sites throughout Northern California, British Columbia (Cariboo and Redstone), Romania, Mexico, France (Torce), Dominican Republic, and Madagascar. 'Our partnership with DCM demonstrates Atlantic Packaging Group of Companies' values and commitments to environmental leadership and collaborative innovation,' said Larissa Fritzen, Plant Manager, Atlantic Packaging Products' Retail Packaging & Display Division, Ontario. 'As a corrugated packaging leader, we are redefining packaging solutions to meet industry demands and contribute to the best sustainable practices. The PrintReleaf initiative, an important part of our ESG strategy, helps reduce environmental impact and preserve resources for future generations.' 'We believe it's our responsibility to operate more sustainably and we recognize that we're a major part of our clients' supply chains which is why we're happy to make this program available to them,' said Richard Kellam, President & CEO of DCM. 'Congratulations to Atlantic Packaging on having made such a significant impact on global reforestation. We can't wait to see more companies hit this impressive milestone.' 1 Data on the number of trees planted provided by PrintReleaf as of February 2025. About DATA Communications Management Corp. DCM is a leading Canadian tech-enabled provider of print and digital solutions that help simplify complex marketing communications and operations workflow. DCM serves over 2,500 clients including 70 of the 100 largest Canadian corporations and leading government agencies. Our core strength lies in delivering individualized services to our clients that simplify their communications, including customized printing, highly personalized marketing communications, campaign management, digital signage, and digital asset management. From omnichannel marketing campaigns to large-scale print and digital workflows, our goal is to make complex tasks surprisingly simple, allowing our clients to focus on what they do best. About Atlantic Packaging Products Atlantic Packaging Products, a North American leader in innovative and sustainable packaging, offers solutions ranging from corrugated and decorative packaging to recycling services and paper bags. With headquarters in Canada and divisions in the United States, the Atlantic Packaging group of companies is committed to consistently meeting customers' expectations through collaboration, innovation, and lasting partnerships. Additional information relating to Atlantic Packaging Products is available on Additional information relating to DATA Communications Management Corp. is available on and in the disclosure documents filed by DATA Communications Management Corp. on SEDAR+ at FORWARD-LOOKING STATEMENTS Certain statements in this press release constitute 'forward-looking' statements that involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance, objectives or achievements of DCM, or industry results, to be materially different from any future results, performance, objectives or achievements expressed or implied by such forward-looking statements. When used in this press release, words such as 'may,' 'would,' 'could,' 'will,' 'expect,' 'anticipate,' 'estimate,' 'believe,' 'intend,' 'plan,' and other similar expressions are intended to identify forward-looking statements. These statements reflect DCM's current views regarding future events and operating performance, are based on information currently available to DCM, and speak only as of the date of this press release. These forward-looking statements involve a number of risks, uncertainties, and assumptions. They should not be read as guarantees of future performance or results and will not necessarily be accurate indications of whether or not such performance or results will be achieved. Many factors could cause the actual results, performance, objectives or achievements of DCM to be materially different from any future results, performance, objectives or achievements that may be expressed or implied by such forward-looking statements. We caution readers of this press release not to place undue reliance on our forward-looking statements since a number of factors could cause actual future results, conditions, actions, or events to differ materially from the targets, expectations, estimates or intentions expressed in these forward-looking statements. Data on the number of trees planted cited in this press release was provided by PrintReleaf. Although DCM believes this data is reliable, DCM has not independently verified the data or the underlying assumptions and cannot guarantee the accuracy or assumptions. The terms 'ESG' and 'sustainability' and similar terms, taxonomies, methodologies, criteria and standards are evolving in terms of both meaning and scope. DCM's use of such terms may vary over time to reflect this evolution. Any use of such terms in this press release are intended as references to DCM's internally defined criteria and not to any jurisdiction-specific regulatory definitions or voluntary standard that may exist. Additional factors are discussed elsewhere in this press release and under the headings "Liquidity and capital resources" and 'Risks and Uncertainties' in DCM's Management Discussion and Analysis and in DCM's other publicly available disclosure documents, as filed by DCM on SEDAR+. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results may vary materially from those described in this press release as intended, planned, anticipated, believed, estimated, or expected. Unless required by applicable securities law, DCM does not intend and does not assume any obligation to update these forward-looking statements.
